A Three-Year Wait? Biocon Set To Weigh US Eylea Judgment
Regulatory Exclusivity For Blockbuster Biologic Expires In Four Months
A bench trial closely watched since June last year has delivered a verdict – although it’s not a completely happy picture for US Eylea (aflibercept) biosimilar hopeful Biocon.
